Pdt Partners, LLC Jounce Therapeutics, Inc. Transaction History

Pdt Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $75,645 - $131,028	-15,009 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $17,594 - $28,504	2,674 Added 21.68%	15,009 $102,000
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $83,014 - $171,086	12,335 New	12,335 $127,000
Q2 2020 Aug 14, 2020	SELL	$4.17 - $7.58 $258,406 - $469,717	-61,968 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.91 - $8.7 $141,717 - $423,689	48,700 Added 367.05%	61,968 $294,000

Q4 2019 Feb 14, 2020	SELL	$2.81 - $9.21 $38,305 - $125,550	-13,632 Reduced 50.68%	13,268 $116,000
Q3 2019 Nov 14, 2019	SELL	$3.33 - $4.93 $12,654 - $18,734	-3,800 Reduced 12.38%	26,900 $90,000
Q2 2019 Aug 14, 2019	SELL	$4.3 - $6.73 $53,371 - $83,532	-12,412 Reduced 28.79%	30,700 $152,000
Q1 2019 May 15, 2019	BUY	$3.43 - $6.87 $147,874 - $296,179	43,112 New	43,112 $267,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.